OncoMatch/Clinical Trials/NCT06055959
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Is NCT06055959 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies Zilucoplan for generalized myasthenia gravis.
Treatment: Zilucoplan — The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: CHRNA1 positive serologic test
diagnosis of generalized myasthenia gravis (gMG) confirmed by a prior positive serologic test result to acetylcholine receptor (AChR)
Excluded: MUSK positive serology
Participant has known positive serology for muscle-specific kinase
Disease stage
Required: Stage MGFA II, MGFA III, MGFA IV (MGFA Clinical Classification)
Excluded: Stage MINIMAL MANIFESTATION STATUS
Participant meets the criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IV at Screening
Demographics
Prior therapy
Cannot have received: thymectomy
Participant has had a thymectomy within 6 months prior to Baseline
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mg0014 50168 · Chicago, Illinois
- Mg0014 50574 · Flower Mound, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06055959 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior thymectomy disqualifies patients from enrollment.
Does this trial require CHRNA1?
Yes, CHRNA1 positive serologic test is a required biomarker for enrollment.
Are patients with MUSK alterations eligible?
No. MUSK positive serology is an exclusion criterion.
What disease stage is eligible?
Stage MGFA II or MGFA III or MGFA IV is required.
Is there an age limit?
Yes. Patients must be 17 years or younger and at least 12 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify